Beijing, China

Peking Union Medical College is among the most selective medical colleges in the People's Republic of China, located in Beijing. It is a relatively independent institution affiliated with Tsinghua University which is one of the top two universities in China. Peking Union Medical College graduates receive Peking Union Medical College diploma signed by both the Peking Union Medical College and Tsinghua presidents. The Hospital and College is located at No.9 Dongdan 3rd Alley, Dongcheng, Beijing, next to the Wangfujing shopping area. Wikipedia.


Time filter

Source Type

News Article | May 5, 2017
Site: www.scientificcomputing.com

A collaboration between stroke neurologists at the Medical University of South Carolina (MUSC) and bioengineers at the University of Massachusetts has led to the creation of a realistic, 3D-printed phantom of a stenotic intracranial artery that is being used to standardize protocols for high-resolution MRI, also known as vessel-wall MRI, at a network of U.S. and Chinese institutions, according to an article published online March 9, 2017 by the Journal of NeuroInterventional Surgery. High-resolution or vessel-wall MRI has been used to study the plaque components in vessels in the brain for more than ten years and has the potential to elucidate the underlying pathology of intracranial atherosclerotic disease (ICAD), the leading cause of stroke worldwide, as well as to gauge patient risk and inform clinical trials of new therapies. However, progress has been stymied by the lack of standardization in high-resolution MRI protocols, which poses an obstacle to multicenter trials. "There is a lot of exciting research that is possible with high-resolution MRI techniques, but it has much less opportunity to affect patient care if it can't be systematically distributed to multiple sites and multiple populations," says Tanya N. Turan, M.D., director of the MUSC Stroke Division and senior author of the article. To overcome this obstacle, Turan worked with bioengineers at the University of Massachusetts to produce a phantom of a stenotic intracranial vessel using imaging sequences obtained from a single patient with ICAD at MUSC. The 3-D printed ICAD phantom mimics both the stenotic vessel and its plaque components, including the fibrous cap and the lipid core. The phantom is being shared with collaborating institutions so that it can be used to standardize high-resolution MRI protocols. The imaging data presented in the Journal of NeuroInterventional Surgery article demonstrate the feasibility of using the phantom for standardization and were obtained from six U.S. and two Chinese sites. Producing the phantom was a major step in the right direction for standardizing high-resolution MRI ICAD protocols. However, several more years may be necessary to complete the process. The next major challenge for these investigators will be establishing parameters for MRI machines from a variety of manufacturers. So far, MRI parameters have been established for Siemens and GE systems but work is still under way on Philips systems. The phantom is also being shared with sites in China, where the burden of intracranial stenosis is especially high. Turan is collaborating with Weihai Xu, M.D., of Peking Union Medical College, the lead Chinese site, to collect additional data to assess interrater reliability among the participating institutions. Once high-resolution MRI protocols have been standardized and good interrater reliability demonstrated, the international team plans to conduct a prospective observational trial to examine risk prediction at participating centers, which would more quickly meet the required patient enrollment than would a trial conducted in the U.S. alone. "We're only going to be able to advance the field more quickly if we work together," says Turan. "The phantom gives us the tool to be able to work together."


News Article | May 5, 2017
Site: www.scientificcomputing.com

A collaboration between stroke neurologists at the Medical University of South Carolina (MUSC) and bioengineers at the University of Massachusetts has led to the creation of a realistic, 3D-printed phantom of a stenotic intracranial artery that is being used to standardize protocols for high-resolution MRI, also known as vessel-wall MRI, at a network of U.S. and Chinese institutions, according to an article published online March 9, 2017 by the Journal of NeuroInterventional Surgery. High-resolution or vessel-wall MRI has been used to study the plaque components in vessels in the brain for more than ten years and has the potential to elucidate the underlying pathology of intracranial atherosclerotic disease (ICAD), the leading cause of stroke worldwide, as well as to gauge patient risk and inform clinical trials of new therapies. However, progress has been stymied by the lack of standardization in high-resolution MRI protocols, which poses an obstacle to multicenter trials. "There is a lot of exciting research that is possible with high-resolution MRI techniques, but it has much less opportunity to affect patient care if it can't be systematically distributed to multiple sites and multiple populations," says Tanya N. Turan, M.D., director of the MUSC Stroke Division and senior author of the article. To overcome this obstacle, Turan worked with bioengineers at the University of Massachusetts to produce a phantom of a stenotic intracranial vessel using imaging sequences obtained from a single patient with ICAD at MUSC. The 3-D printed ICAD phantom mimics both the stenotic vessel and its plaque components, including the fibrous cap and the lipid core. The phantom is being shared with collaborating institutions so that it can be used to standardize high-resolution MRI protocols. The imaging data presented in the Journal of NeuroInterventional Surgery article demonstrate the feasibility of using the phantom for standardization and were obtained from six U.S. and two Chinese sites. Producing the phantom was a major step in the right direction for standardizing high-resolution MRI ICAD protocols. However, several more years may be necessary to complete the process. The next major challenge for these investigators will be establishing parameters for MRI machines from a variety of manufacturers. So far, MRI parameters have been established for Siemens and GE systems but work is still under way on Philips systems. The phantom is also being shared with sites in China, where the burden of intracranial stenosis is especially high. Turan is collaborating with Weihai Xu, M.D., of Peking Union Medical College, the lead Chinese site, to collect additional data to assess interrater reliability among the participating institutions. Once high-resolution MRI protocols have been standardized and good interrater reliability demonstrated, the international team plans to conduct a prospective observational trial to examine risk prediction at participating centers, which would more quickly meet the required patient enrollment than would a trial conducted in the U.S. alone. "We're only going to be able to advance the field more quickly if we work together," says Turan. "The phantom gives us the tool to be able to work together."


Since its inception, MMAAP foundation has awarded over 40 Fellowship and Project grants to support the work of exceptional physician scientists and investigators with the vision, drive and dedication to find new and innovative ways towards advancements in the targeted medical fields. These outstanding award recipients represent more than 20 prestigious Chinese medical institutions including Peking Union Medical College Hospital, Xijing Hospital, the Fourth Military Medical University, Peking University Institute of Hematology, West China Hospital, Sichuan University, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, and others. "The visionary leadership of MMAAP Foundation Chairman and Founder, Howard P. Milstein, has brought together and funded exchanges between outstanding researchers, medical talent, and institutions in these regions," said Sean X. Leng, MD, PhD, President of MMAAP Foundation. "The 2017 recipients are among the most talented investigators in their fields and our support of their work is vital to both furthering medical research and strengthening relations between the U.S. and China." Grant applications were evaluated through a two-step peer review process according to the National Institute of Health standard. Panels of Chinese and U.S. experts in their respective fields jointly reviewed all proposals, and finalists were submitted for approval by MMAAP Foundation. The U.S. panels in Geriatrics, Skin Disease, Hematology, Reproductive Medicine, and Translational Medicine include members of the American Geriatrics Society, Medical Advisory Committee of American Skin Association, New York Blood Center, Jones Foundation for Reproductive Medicine, as well as members of other leading U.S. institutions in each field. The mission of Milstein Medical Asian American Partnership Foundation (MMAAP Foundation) is to improve world health by developing mutually beneficial partnerships between the U.S. and China, as well as greater Asia. Working with some of the premier health organizations in the world, MMAAP Foundation brings together and funds exchanges among the best research, medical talent, and institutions in the regions. This strategy is a high priority for MMAAP Foundation's founder Howard P. Milstein. MMAAP Foundation is a 501(c) (3) non-profit organization. For more than 50 years, the Milstein family has been actively involved in health-related and medical philanthropy. MMAAP Foundation builds upon this distinguished history in five areas: Senior Healthcare, Skin Disease and Melanoma, Reproductive Biology, Blood Research, and Translational Medicine. MMAAP Foundation works in close collaboration with other medical organizations supported by the Milstein family, including American Skin Association, Milstein Melanoma Research Program at The Rockefeller University, Howard and Georgeanna Jones Foundation for Reproductive Medicine, New York Blood Center, and the Program for Translational Chemical Biology at New York-Presbyterian Hospital/Weill Cornell Medical Center. For more information, please visit MMAAP Foundation's website at www.mmaapf.org. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/milstein-medical-asian-american-partnership-foundation-announces-2017-fellowship-and-project-awards-300447740.html


HONG KONG, April 28, 2017 /PRNewswire/ -- Digital China Holdings Limited ("DC Holdings" or the "Group"; stock code: 00861.HK, 910861.TW), China's largest integrated IT service provider, is pleased to announce that the signing ceremony of China Healthcare Big Data Development Co., Ltd. (CHBDDC) was held in Beijing. DC Holdings initiated the establishment of CHBDDC. Guo Wei, Chairman of DC Holdings, and Jin Xiaotao, Deputy Director of National Health and Family Planning Commission, delivered speech at the ceremony. Lu Jiang, Vice Mayor of Xia'men, representatives of Changzhou Municipal Government, China Population and Development Research Center, Peking Union Medical College Hospital, Peking University, and Philips (China) Investment Co., Ltd attended the signing ceremony. Under the guidance of National Health and Family Planning Commission, CHBDDC was initiated by DC Holdings, and cosponsored by Industrial and Commercial Bank of China Limited, Bank of China Limited, Chinese Academy of Sciences Holding Co., Ltd.,China Telecom Corporation Limited, China Cinda Asset Management Co., Ltd., Shougang Corporation, Guangzhou Urban Construction Investment Group Co., Ltd., Wonders Information Co., Ltd., Neusoft Corporation, Inspur and Ylz Information Technology, Bringspring Science and Technology Co., Ltd. and many other central enterprises, state-owned enterprises and well-known listed companies. The new company will respond to the country's policy guidelines to promote the "Interconnection, Open Sharing" of Big Data in healthcare and promote the supply-side structural reform on healthcare and fulfill the mission of "Digitalised China" for the benefit of the people. Based on the top-level design for industrial parks of healthcare Big Data and combined with the development plan of "Healthy China", CHBDDC will be undertaking the construction of national and local industrial parks of healthcare Big Data. CHBDDC will put effort in the construction of Big Data center, Big Data platform, medical services, healthcare services, integrated management, precision medicine, delicacy insurance, insurance audit, medical payment and other key areas, to promote a full layout and construction of industrial parks of healthcare Big Data, and to become a new support for medical reform and a new driver of local economy. The new company will serve as a platform to integrate the relevant advantages of state-owned enterprises and listed enterprises: to invest and operate the National Healthcare Big Data Center and industrial parks so as to build a service system of healthcare Big Data under the principles of "Government-led, Commercial Operation and Joint Innovation for Win-win"; to open up the data of the whole industry chain to build a Sm@rt Big Data ecology; to utilize financial means for the promotion of incubation and cultivation of health industry and to build a large healthcare data ecosystem and develop the construction of healthcare Big Data. DC Holdings upholds its mission to drive the "Digitalised China". Combined with technology and capital, DC Holdings has formed cloud computing and Big Data as core capabilities. The Company is working towards the transformation to cloud computing and Big Data based on the ecological circle created through internal bottom-up innovation system and external investment for M&As and with Sm@rt City, modern agriculture, precision medicine and intelligent manufacturing as core business areas. The integration of healthcare resources and building up the integration platform by DC Holdings will fully demonstrate the benefit of health Big Data. As one of the key parts in DC Holdings' core business areas, Digital China Health is determined to build the top brand of healthcare Big Data in China by providing comprehensive and accurate information services and cancer-related data services. About Digital China Holdings Limited Digital China Holdings Limited ("DC Holdings", Stock Code: 0861.HK) was listed on the Main Board of The Stock Exchange of Hong Kong in 2001 following a successful spin-off from the then Legend Group in 2000. It has developed its capital platforms across Mainland China, Hong Kong and Taiwan through the following four listed companies – DC Holdings, Digital China Information Service Company Ltd., Digiwin Software Company Ltd., and HC International, Inc. Their combined market capitalization reaches nearly HK$50 billion. Since its listing 16 years ago, DC Holdings has adhered to the mission of driving the "Digitalization in China". With the corporate value of "Commitment, Passion and Innovation", the Company evolved from China's largest IT product distributor into the largest integrated IT services provider and then the most influential Sm@rt City solutions provider in China. According to its latest development strategy, DC Holdings will capture the opportunities arising from the "Internet +" strategy and leverage on its technological strengths and capital resources to drive breakthroughs in Sm@rt City, precision healthcare, modern agriculture and Sm@rt manufacturing based on the Cloud computing and Big Data technology. With comprehensive innovation mechanism and multi-layer incubation system, the Company is determined to become a genuine innovative enterprise. For additional information about DC Holdings, please visit the Group's website at www.dcholdings.com.hk. For investor and media inquiries: Charles Chan Emma Liang PRChina Limited PRChina Limited Tel: 852-2522-1838 Tel: 852-2522-1838 Email: ckchan@prchina.com.hk Email: eliang@prchina.com.hk Digital China Holdings Limited Tel: 852-3416-8000 Email: ir@digitalchina.com   To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dc-holdings-initiates-the-establishment-of-china-healthcare-big-data-development-co-ltd-to-construct-the-healthcare-big-data-ecosystem-300447914.html


Deep Learning Platform from Startup Infervision Acts as Second Pair of Eyes to Find Suspicious Lesions and is World's First to Reshape the Workflow of Radiologists SAN JOSE, CA / ACCESSWIRE / May 8, 2017 / (GPU Tech Conference) Infervision, a tech company using big data and artificial intelligence to assist and improve medical diagnoses, is introducing its innovative, deep learning solution to help radiologists identify suspicious lesions and nodules in lung cancer patients faster than ever before. The Infervision AI platform is the world's first to reshape the workflow of radiologists and it is already showing dramatic results at several top hospitals in China. The company founder, Chen Kuan, will present a talk on the company and its use of AI for medical diagnoses at the NVIDIA GPU Tech Conference in San Jose (Monday, May 8, 9-9:50AM PT). Infervision's AI-aided CT diagnosis, with its high-performance parallel computing power, effectively learns the core characteristics of lung cancer and efficiently detects suspected cancer features in different CT image sequences, helping with early diagnosis and, consequently, early treatment. The technology is also used to assist in X-ray diagnosis and has achieved extremely high accuracy so that it is close to that of a deputy chief physician in the diagnosis of cardiothoracic diseases at one of the top Chinese hospitals where the software is now in use. For the past six months, the technology has been in use at several top hospitals in China, a country experiencing hundreds of thousands of new lung cancer patients annually, while it has too few radiologists. After rigorous testing and integrating the software with the standard PACS (Picture Archiving and Communication System), Infervision's technology is proving to be extremely effective and is enhancing the work of Chinese doctors by acting as a second pair of eyes. The Infervision solution improves the workflow of radiologists, delivering a faster reading of hundreds of images for each patient, and bringing to the doctor's attention those scans that may have malignant lesions or nodules so radiologists will thoroughly review them. "Our goal at Infervision is to build a stronger medical industry and help accelerate diagnoses, which is so important for patients," said Chen Kuan, founder and CEO of Infervision. "In China, we have a severe shortage of radiologists, particularly in lower-level hospitals all over the country. There are 80,000 radiologists who must diagnose 1.4 billion radiology scans a year. By using artificial intelligence and deep learning, the Infervision platform augments the work of these doctors so they can get through scans quickly. A process that used to take 15 minutes can be dramatically reduced so detection and treatment of lung cancer is faster. This could be life changing for many." Additionally, Infervision's technology and a group of radiologists recently went head-to-head in a report reading experiment with different types and sizes of nodules. Infervision's AI-CT predicted more accurately than radiologists in every category. "In no way will this technology ever replace doctors. It is intended to eliminate much of the highly repetitive work. Infervision empowers doctors and helps them deliver more accurate reports and do it much faster," continued Kuan. The Infervision artificial intelligence continues to learn as more data becomes available and also as it analyzes past results. Lung cancer is particularly rampant in China, due to both air pollution and smoking, with between 600,000 and 700,000 new lung cancer cases are diagnosed annually. While this is an unfortunate statistic, it provides a huge trove of medical data that can make the Infervision technology stronger and even more effective. Infervision specializes in assisted medical image diagnosis, using artificial intelligence and deep learning to help improve the workflow and efficiency of radiologists for diagnosing various types of cancer and other diseases. The company has raised a Series A round of 50M RMB ($7.2M USD) led by Sequoia Capital and established cooperative business partnerships with close to 20 Tertiary Grade A hospitals, including Peking Union Medical College Hospital and Shanghai Changzheng Hospital. It also has relationships with online and offline medical image platforms, including Ali Cloud Computing, and has entered into strategic partnerships with GE Healthcare, Cisco, and NVIDIA. Founders and scientists with Infervision studied at top universities and research institutions around the world. For more information, visit www.infervision.com.


BACKGROUND: Oesophageal cancer is one of the most deadly forms of cancer worldwide. Long non-coding RNAs (lncRNAs) are often found to have important regulatory roles.OBJECTIVE: To assess the lncRNA expression profile of oesophageal squamous cell carcinoma (OSCC) and identify prognosis-related lncRNAs.METHOD: LncRNA expression profiles were studied by microarray in paired tumour and normal tissues from 119 patients with OSCC and validated by qRT-PCR. The 119 patients were divided randomly into training (n=60) and test (n=59) groups. A prognostic signature was developed from the training group using a random Forest supervised classification algorithm and a nearest shrunken centroid algorithm, then validated in a test group and further, in an independent cohort (n=60). The independence of the signature in survival prediction was evaluated by multivariable Cox regression analysis.RESULTS: LncRNAs showed significantly altered expression in OSCC tissues. From the training group, we identified a three-lncRNA signature (including the lncRNAs ENST00000435885.1, XLOC_013014 and ENST00000547963.1) which classified the patients into two groups with significantly different overall survival (median survival 19.2 months vs >60 months, p<0.0001). The signature was applied to the test group (median survival 21.5 months vs >60 months, p=0.0030) and independent cohort (median survival 25.8 months vs >48 months, p=0.0187) and showed similar prognostic values in both. Multivariable Cox regression analysis showed that the signature was an independent prognostic factor for patients with OSCC. Stratified analysis suggested that the signature was prognostic within clinical stages.CONCLUSIONS: Our results suggest that the three-lncRNA signature is a new biomarker for the prognosis of patients with OSCC, enabling more accurate prediction of survival. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.


MicroRNAs have been shown to play an important role in normal hematopoisis and leukemogenesis. Here, we report function and mechanisms of miR-181 family in myeloid differentiation and acute myeloid leukemia (AML). The aberrant overexpression of all the miR-181 family members (miR-181a/b/c/d) was detected in French-American-British M1, M2 and M3 subtypes of adult AML patients. By conducting gain- and loss-of-function experiments, we demonstrated that miR-181a inhibits granulocytic and macrophage-like differentiation of HL-60 cells and CD34+ hematopoietic stem/progenitor cells (HSPCs) by directly targeting and downregulating the expression of PRKCD (which then affected the PRKCD-P38-C/EBPα pathway), CTDSPL (which then affected the phosphorylation of retinoblastoma protein) and CAMKK1. The three genes were also demonstrated to be the targets of miR-181b, miR-181c and miR-181d, respectively. Significantly decreases in the expression levels of the target proteins were detected in AML patients. Inhibition of the expression of miR-181 family members owing to Lenti-miRZip-181a infection in bone marrow blasts of AML patients increased target protein expression levels and partially reversed myeloid differentiation blockage. In the mice implanted with AML CD34+ HSPCs, expression inhibition of the miR-181 family by Lenti-miRZip-181a injection improved myeloid differentiation, inhibited engraftment and infiltration of the leukemic CD34+ cells into the bone marrow and spleen, and released leukemic symptoms. In conclusion, our findings revealed new mechanism of miR-181 family in normal hematopoiesis and AML development, and suggested that expression inhibition of the miR-181 family could provide a new strategy for AML therapy.Oncogene advance online publication, 1 September 2014; doi:10.1038/onc.2014.274.


Lung cancer is the leading cause of cancer-related death in the world. To explore tumor biomarkers for clinical application, two-dimensional fluorescence difference gel electrophoresis and subsequent MALDI-TOF/TOF mass spectrometry were performed to identify proteins differentially expressed in 12 pairs of lung squamous cell tumors and their corresponding normal tissues. A total of 28 nonredundant proteins were identified with significant alteration in lung tumors. The up-regulation of isocitrate dehydrogenase 1 (IDH1), superoxide dismutase 2, 14-3-3ε, and receptor of activated protein kinase C1 and the down-regulation of peroxiredoxin 2 in tumors were validated by RT-PCR and Western blot analysis in independent 15 pairs of samples. Increased IDH1 expression was further verified by the immunohistochemical study in extended 73 squamous cell carcinoma and 64 adenocarcinoma clinical samples. A correlation between IDH1 expression and poor overall survival of non-small cell lung cancer (NSCLC) patients was observed. Furthermore, ELISA analysis showed that the plasma level of IDH1 was significantly elevated in NSCLC patients compared with benign lung disease patients and healthy individuals. In addition, knockdown of IDH1 by RNA interference suppressed the proliferation of NSCLC cell line and decreased the growth of xenograft tumors in vivo. These observations suggested that IDH1, as a protein promoting tumor growth, could be used as a plasma biomarker for diagnosis and a histochemical biomarker for prognosis prediction of NSCLC.


The present invention discloses a method for purification of bacterial capsular polysaccharide at low temperature(<20C) by salt-induced two-phase aqueous micellar system with TritonX-114 and can significantly reduce the endotoxins. Impurity proteins and the endotoxins need to be removed as many as possible in the preparation process of bacterial capsular polysaccharide vaccine to reduce the side reaction of the vaccines. Currently, the phenol extraction method, column chromatography and ethanol precipitation method all have a number of drawbacks. As compared with the phenol, the nonionic detergent has the advantages such as non-corrosiveness and non-carcinogenicity, and does not cause harm to the environment. As compared with the column chromatography, the method of the present invention is large in throughput, time-saving, economical, and easily expanding the scale production, which is a safe, environment-friendly and efficient.


Patent
Peking Union Medical College and Shenzhen Mindray Bio Medical Electronics Co. | Date: 2015-06-17

This disclosure relates to devices and systems for real-time recognition of restoration of spontaneous circulation (ROSC) in cardio-pulmonary resuscitation (CPR) process. Recognition mechanisms in both time domain and frequency domain are provided for the ROSC recognition, where the time-domain recognition logic may detect the ROSC by recognizing envelope features of sampled signals in the time domain, and the frequency-domain recognition logic may detect the ROSC by recognizing spectral peaks at different frequency points continuously or significant variations of amplitude of spectral peaks in the frequency spectrum. Acquiring pulse oximetry waveform signals of a patient.

Loading Peking Union Medical College collaborators
Loading Peking Union Medical College collaborators